RXRX Stock Grinds Higher As AI Drug Pipeline Shows Real Progress

Recursion Pharmaceuticals Inc. stocks have been trading up by 7.58 percent on optimism around its latest AI-driven drug discovery advances.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading RXRX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Q1 2026 showed a smaller‑than‑expected loss for RXRX with EPS at -$0.22 versus -$0.26 consensus, plus stronger revenue and an extended cash runway into early 2028.
Positive early data across multiple oncology programs and strong Phase 2 signals in familial adenomatous polyposis suggest Recursion’s AI platform is starting to translate into real clinical traction.
JPMorgan trimmed its RXRX price target to $10 from $11 but kept an Overweight rating, still signaling constructive long‑term conviction.
Morgan Stanley nudged its Recursion target up to $5.50 from $5.00 while maintaining Equal Weight, pointing to measured optimism and balanced risk.
Founder Chris Gibson will exit the Board after 2026/06 but remain a strategic advisor, while leadership emphasizes continuity and focus on the AI‑driven drug discovery roadmap.

Live Update At 12:33:23 EDT: On Wednesday, May 27, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending up by 7.58%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

RXRX has been slowly grinding higher on the chart. Over the last couple of weeks, Recursion Pharmaceuticals has bounced from the $2.85–$2.90 area to close around $3.19. That is not a parabolic move, but it is a steady uptrend with higher lows, which short‑term traders like to see.

The intraday 5‑minute chart shows RXRX opening near $2.94 and then pushing through $3.00, $3.10, and briefly testing the mid‑$3.20s before consolidating around $3.19. The range is tight, and volume‑style action looks like accumulation rather than panic. Day traders watching RXRX can treat $3.00 as a key support line and the $3.30–$3.45 zone as near‑term resistance based on recent highs.

More Breaking News

Under the hood, Recursion is still a heavy cash‑burn AI biotech. Q1 2026 revenue was about $74.7M on a trailing basis, but margins are deeply negative, with Return on Equity and Return on Assets both sharply below zero. The key offset is the balance sheet: RXRX ended the quarter with roughly $654M in cash and short‑term investments, a current ratio around 5.5, and very low debt. For traders, that extended runway to early 2028 means dilution risk is pushed out, which can support sentiment on every positive data headline.

Why Traders Are Watching RXRX Right Now

RXRX is one of those names where the story and the stats finally line up for momentum‑style trading. On 2026/05/06, Recursion Pharmaceuticals reported Q1 numbers that beat expectations on the bottom line. The loss came in at -$0.22 per share versus the -$0.26 Wall Street expected, and management reiterated that current cash should last into early 2028. For a pre‑profit biotech leaning hard on AI‑driven drug discovery, that runway is huge. It removes one of the biggest overhangs traders usually worry about: surprise financings.

The same Q1 2026 update offered more than just accounting wins. RXRX highlighted positive early clinical data across multiple oncology programs and strong Phase 2 signals in familial adenomatous polyposis. That tells traders the AI platform is not just hype; it is feeding a pipeline that is beginning to generate measurable signals in humans. Progress in partnered AI‑driven discovery adds a secondary validation layer, because big‑pharma collaborators do their own due diligence before committing capital or milestones.

Wall Street has noticed. JPMorgan cut its RXRX price target from $11 to $10 but kept an Overweight rating, which is still a clear “we like this name” stance. Morgan Stanley bumped its target from $5.00 to $5.50 and held an Equal Weight rating, signaling a balanced view but leaning slightly more positive. Mixed analyst labels like these can create great trading ranges as different camps battle it out on the tape.

Beyond the core business, Recursion’s Altitude Lab accelerator has seen portfolio companies raise more than $205M since 2020. That ecosystem effect keeps RXRX in the center of a growing Salt Lake City biotech hub, which can feed talent, deal flow, and future headlines that momentum traders hunt.

Conclusion

RXRX sits at an interesting crossroads where story, cash, and chart are starting to align. The company just printed a smaller‑than‑expected Q1 loss, showed “extremely strong” top‑line performance versus expectations, and again told the market its cash runway should last into early 2028. That buys time for Recursion Pharmaceuticals to work its AI‑driven drug discovery engine and push more candidates through oncology and rare‑disease trials.

Traders still need to respect the risk. RXRX is deeply unprofitable, burning more than $80M in free cash flow in the last quarter, and the income statement is covered in red ink. Founder Chris Gibson stepping off the Board after 2026/06 is another headline that can spook weak hands, even though he will remain a strategic advisor and leadership is guiding to continuity. For active traders, volatility around data updates and analyst notes is the real opportunity.

The key is treating RXRX like any speculative biotech or AI name: manage risk, trade the levels, and stay disciplined. As Tim Bohen, lead trainer with StocksToTrade says, “For me, trading is more about managing risk than finding the next big mover.” Tim Sykes hammers this home all the time: “Cut losses quickly, because big losses are account killers.” For RXRX, that means sizing small, honoring your stops around key support like $3.00, and only pressing when the chart, news, and volume all line up in your favor. This is educational and research content only, but the RXRX story is one every serious momentum trader should be tracking closely.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!